Publications by authors named "Francisco A M O Cariri"
Human papillomavirus (HPV) infection is responsible for all cervical cancer cases, other anogenital cancers, and head and neck tumors. The epidemiological relevance of HPV-induced tumors reinforces the need for the development of therapeutic antitumor vaccines. Clinical trials with different vaccine formulations, particularly DNA vaccines, have provided promising results but have still been unable to achieve the immunogenicity required for use in infected patients.
View Article and Find Full Text PDFArticle Synopsis
- Millions globally are infected with HPV, HSV, or HIV, driving the need for effective vaccines to combat these viruses and their related cancers.
- Researchers have developed a new strategy using bicistronic DNA vaccines that target antigens from all three viruses simultaneously, showing promise in mouse models.
- The vaccines stimulated strong immune responses, demonstrating potential for preventing or treating infections and cancers linked to HPV, HSV, and HIV.
Article Synopsis
- The dengue virus non-structural 1 (NS1) protein is important for evading immune defenses and can be targeted for vaccine development due to its correlation with protective immunity.
- In a study, BALB/c mice were vaccinated with a recombinant NS1 protein paired with various adjuvants, including LT(G33D), which resulted in a significant immune response and 50% protective immunity against dengue virus type 2 (DENV2).
- Mice vaccinated with LT(G33D) showed stronger antibody responses along with fewer side effects compared to those vaccinated with Freund’s adjuvant, indicating a safer and more effective vaccine formulation.
Type 1 herpes virus (HSV-1) glycoprotein D (gD) enhances antigen-specific immune responses, particularly CD8(+) T cell responses, in mice immunized with DNA vaccines encoding hybrid proteins genetically fused with the target antigen at a site near the C-terminal end. These effects are attributed to the interaction of gD with the herpes virus entry mediator (HVEM) and the concomitant blockade of a coinhibitory mechanism mediated by the B- and T-lymphocyte attenuator (BTLA). However, questions concerning the requirement for endogenous synthesis of the antigen or the adjuvant/antigen fusion itself have not been addressed so far.
View Article and Find Full Text PDF